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A B S T R A C T
Canine idiopathic pulmonary ﬁbrosis (CIPF) affects middle-aged to older dogs of a single breed, mainly
the West Highland white terrier (WHWT), which is suggestive of a genetic predisposition. CIPF causes
exercise intolerance, restrictive dyspnoea and coughing. Coarse crackles are heard on thoracic
auscultation. Abnormal blood gas parameters and a shortened ‘6-min-walking test’ distance are
common; secondarily induced pulmonary hypertension and/or airway collapse are frequent. These
features of CIPF mimic those of idiopathic pulmonary ﬁbrosis (IPF) in humans and therefore identify CIPF
as a possible spontaneously arising model for study of human IPF. However, computed tomographic and
histopathological ﬁndings of CIPF are not identical to those of human IPF. As in human IPF, the aetiology of
CIPF is not yet fully elucidated. There are no curative treatments and the prognosis is poor. This paper
reviews advances in understanding of the clinical description and natural history of CIPF, the
investigation of biomarkers and the exploration of possible aetiologies and mechanistic hypotheses.
© 2018 Elsevier Ltd. All rights reserved.
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Canine idiopathic pulmonary ﬁbrosis (CIPF) is a spontaneously
arising chronic and progressive ﬁbrotic lung disease of unknown
aetiology that affects older West Highland white terriers
(WHWTs). Corcoran et al. (1999a) initially described the condition
in a cohort of 29 WHWTs with marked inspiratory crackles audible
on auscultation of the thorax in association with interstitial
changes radiographically. Additional case reports and case series
were published and allowed improved clinical characterisation of
this disease (Webb and Armstrong, 2002; Norris et al., 2005;
Corcoran et al., 2011; Heikkilä et al., 2011). The clinical entity has
been referred as chronic pulmonary disease (Corcoran et al.,1999a;
Schober and Baade, 2006), chronic idiopathic pulmonary ﬁbrosis
(Lobetti et al., 2001; Webb and Armstrong, 2002), idiopathic
pulmonary ﬁbrosis (Norris et al., 2002), interstitial lung disease
(Norris et al., 2005; Reinero and Cohn., 2007) and, more recently,
CIPF (Johnson et al., 2005; Heikkilä et al., 2011).
This spontaneously arising ﬁbrotic pulmonary disease shares
several clinical and pathogenic features with human IPF and has
been identiﬁed by some authors as a possible model for human IPF,
with the hope that investigation of CIPF would offer a tool for
studying some aspects of the ﬁbrotic mechanisms that might also* Corresponding author.
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1090-0233/© 2018 Elsevier Ltd. All rights reserved.prove useful for human medicine. Such perspectives, in addition to
the interest in the condition in dogs, and in particular for the
WHWT breed, offer an additional incentive for in-depth investiga-
tion of possible pathways leading to ﬁbrosis in CIPF.
The aim of this narrative review is to provide an overview of
published studies related to CIPF.
Prevalence and clinical presentation
The prevalence of CIPF is currently unknown.
CIPF affects mainly middle-aged to older WHWTs, with a mean
age at diagnosis ranging from 9 to 13 years (Corcoran et al., 1999a;
Heikkilä et al., 2011; Roels et al., 2018). Clinical signs may appear
earlier in rare cases, with the earliest onset described at 2 years of
age (Johnson et al., 2005; Schober and Baade., 2006). No sex
predisposition has been reported (Heikkilä-Laurila and Rajamäki,
2014). Rare cases of pulmonary ﬁbrosis have also been described in
other terrier breeds, such as the American Staffordshire terrier, the
Bull terrier, the Cairn terrier and the Scottish terrier (Corcoran
et al., 1999b; Lobetti et al., 2001; Norris et al., 2002; Johnson et al.,
2005; Krafft et al., 2013). However, only very limited data are
available for these other breeds and whether pulmonary ﬁbrosis in
these dogs is the same as in the WHWT breed has not been
investigated.
In WHWTs with CIPF, the disease generally develops slowly and
dogs deteriorate progressively over time (Corcoran et al., 1999a).
Early signs are often attributed by the owners to the normal ageing
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reveals exercise intolerance alone or in association with chronic
cough in an otherwise alert and bright dog; more pronounced
respiratory signs may also be reported, such as tachypnoea,
excessive panting, dyspnoea, cyanosis or syncope (Heikkilä-Laurila
and Rajamäki, 2014). The duration of clinical signs at the time of
diagnosis also varies between individuals and ranges from a few
weeks to several months (Heikkilä-Laurila and Rajamäki, 2014).
One of the most typical clinical features is inspiratory crackles
on thoracic auscultation, which occurs in the majority of the
affected dogs. In some dogs, crackles can even be heard without a
stethoscope when the dog is breathing with an open mouth
(Heikkilä-Laurila and Rajamäki, 2014). Other common clinical
examination ﬁndings include positive laryngo-tracheal reﬂex,
tachypnoea and excessive abdominal breathing (Heikkilä-Laurila
and Rajamäki, 2014). The presence of wheezes on thoracic
auscultation, dyspnoea and cyanosis has also been reported
(Corcoran et al., 1999a).
Understanding the pathogenesis
In recent decades, research efforts have been oriented to
understanding the pathogenesis of human IPF. Previously deﬁned
as an inﬂammatory disease, IPF is currently considered as an
epithelium-driven disease, in which a dysfunctional ageing lung
epithelium is exposed to recurrent micro-injuries leading to
defective attempts to regenerate and aberrant epithelial–mesen-
chymal crosstalk (Daccord and Maher, 2016). Multiple studies have
shown that alveolar epithelial cell (AEC) apoptosis secondary to
injury is followed by extravascular coagulation, immune system
activation and aberrant persistent activation of AECs. These cells, in
turn, induce the migration and proliferation of local ﬁbroblasts,
recruit circulating ﬁbrocytes to areas of injury, and promote
differentiation of ﬁbroblasts into persistently activated myoﬁbro-
blasts, which secrete excessive amounts of extracellular matrix
(ECM) proteins. This pathological cascade involves complex cell–
cell and cell–matrix interactions through numerous biochemical
mediators, such as growth factors, enzymes, chemokines, coagu-
lation factors and reactive oxygen species, all of which have the
potential to be inﬂuenced by numerous host and environmental
factors. TGF-β, a potent pro-ﬁbrotic mediator involved in cell
recruitment, myoﬁbroblast differentiation and induction of ECM
production, is cardinal among these.
In dogs, two studies have investigated how TGF-β1 may be
involved in CIPF (Krafft et al., 2014; Lilja-Maula et al., 2014b). The
ﬁrst aimed to investigate the expression of known extracellular
matrix protein regulators of TGF-β1 storage and activation,
namely latent TGF-β binding protein-1 (LTBP-1) and ﬁbrillin-2,
and expression of the phosphorylated signalling protein Smad2
(P-Smad2) (Lilja-Maula et al., 2014b). These authors reported that
P-Smad2 immunoreactivity, an indicator of TGF-β1 signalling
activity, was increased in WHWTs with CIPF in comparison with
healthy control WHWTs, suggesting enhanced TGF-β1 signalling
in CIPF as part of the pathophysiology of the disease. The second
study aimed to evaluate TGF-β1 biochemical pathways in healthy
dogs and dogs with CIPF (Krafft et al., 2014), using immunohis-
tochemistry and qRT-PCR to measure expression of TGF-β1 and
molecules involved in its storage (LTBP-1, -2 and -4), activation
(αvβ6 and αvβ8 integrins, thrombospondin-1) and signal inhibi-
tion (Smad7). Results suggested that some of the activating,
storage and signalling pathways of TGF-β1 are modiﬁed in
WHWTs with CIPF and may play a role in the pathogenesis of the
disease.
Lilja-Maula et al. (2015) investigated the expression of activins
A and B (cytokines belonging to the TGF-β superfamily) in normal
canine lung tissue and in lung tissue from WHWTs with CIPF, andanalysed activin B in the BALF from healthy WHWTs and WHWTs
with CIPF. Activin B was suggested to play a role in ﬁbrosis and in
pathological alteration of the alveolar epithelium.
Aetiology and risk factors
In people, IPF is believed to arise in genetically susceptible
individuals as a consequence of an aberrant wound-healing
response following repetitive alveolar injury. The exact triggers
initiating the ﬁbrotic process remain unknown. Several risk factors
have been associated with disease development and progression,
although their role in the pathogenesis of the disease remains
unclear. These risk factors include the following: genetic back-
ground; inhalation of cigarette smoke; environmental or occupa-
tional exposure to metal, wood, sand, stone or silica dust (Raghu,
2011; Olson and Swigris, 2012); gastro-oesophageal reﬂux (Minnis
et al., 2016); and exposure to infectious agents, including viruses
(e.g. Epstein–Barr virus), bacteria or fungi (Raghu, 2011; Moly-
neaux and Maher, 2013; Antoniou et al., 2014).
In CIPF, in an attempt to recognise potential triggers, an online
questionnaire–based survey was launched via social media to
WHWT owners (Roels et al., 2018). The parameters signiﬁcantly
associated with CIPF included genetic relationship to a dog affected
by CIPF, living in an old house, absence of a ventilation system, and
frequent grooming in dedicated grooming facilities. These results
indicated an association between CIPF, genetic background and
environmental factors.
In CIPF, the possible role of gastroesophageal reﬂux and micro-
aspiration of small amounts of gastric content was evaluated by
measuring total bile acids in BALF by mass spectrometry in
healthy WHWTs and WHWTs with CIPF, in comparison with BALF
from dogs with other diseases (Maatta et al., 2018). Bile acids
were detected more frequently in healthy WHWTs, compared
with dogs of other breeds and were at higher concentrations in
WHWTs with CIPF than in healthy WHWTs, suggesting that
micro-aspiration could be associated with the predisposition of
WHWT to CIPF.
Limited studies have investigated a possible association
between CIPF and infectious agents. To assess the potential
association between CIPF and canine herpesvirus infection, a PCR
assay was used to test lung and blood samples from WHWTs with
CIPF and control dogs without respiratory disease. Canine
herpesvirus could not be ampliﬁed from the lung and blood
samples from WHWTs with CIPF or samples from control dogs,
making an association between CIPF and herpesvirus infection
very unlikely (Roels et al., 2016).
As mentioned above, CT and histopathological ﬁndings in CIPF
share characteristics of both human UIP and NSIP patterns, the
latter being commonly observed in chronic hypersensitivity
pneumonitis (HP), which is recognised as the main differential
for IPF (Neurohr and Behr., 2015). As cases of chronic HP have been
associated with a fungal aetiology in humans (Spagnolo et al.,
2015; Kouranos et al., 2017), a recent study aimed to investigate a
potential association between fungal infection and CIPF. Lung
specimens from WHWTs with CIPF and healthy WHWTs were
screened for fungal DNA using a conventional pan-fungal PCR assay
targeting the conserved internal transcribed spacer (ITS) region
(Roels et al., 2017b). In the same study, serum samples from the
WHWTs with CIPF and from age-matched unaffected control dogs
were tested for precipitins from 10 species of environmental fungi
using electrosyneresis on cellulose acetate (Roels et al., 2017b). PCR
results suggested that an association between CIPF and invasive
fungal infection or heavy fungal colonisation was unlikely, while
the higher proportion of positive precipitin reactions observed in
dogs with CIPF might suggest a lung sensitisation to inhaled fungal
allergens.
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In human IPF, several genome-wide association studies have
identiﬁed several common and rare genetic variants in more than a
dozen loci on different chromosomes that appear to contribute to
the risk of developing IPF (Fingerlin et al., 2013; Sgalla et al., 2016;
Allen et al., 2017).
In CIPF, despite of the strong predisposition of the WHWT breed
to CIPF, which raises suspicion for a genetic basis (Heikkilä-Laurila
and Rajamäki, 2014), and despite the clear association between
CIPF and genetic background (Roels et al., 2018), genetic studies
have so far failed to identify clear candidate genes.
Diagnostic testing
Accurate diagnostic testing is very challenging because of the
absence of highly sensitive and speciﬁc testing modalities for CIPF.
The most frequently used diagnostic tests (including haemato-
logical and serum biochemical analyses, radiography, blood gas
assessment, bronchoscopy and bronchoalveolar lavage analysis,
echocardiography and the ‘6-min walking test’; 6MWT) are not
able to conﬁrm the diagnosis, but are used to increase the index of
suspicion for CIPF and to rule out comorbidities. By analogy with
human medicine, high-resolution computed tomography (HRCT)
and histopathology are considered to be the most speciﬁc tests to
conﬁrm the diagnosis. However, HCRT ﬁndings in CIPF fail to
parallel HRCT ﬁndings in human IPF (classically characterised by a
so-called ‘usual interstitial pneumonia’ [UIP] pattern) (Roels et al.,
2017a). While the deﬁnitive diagnosis of CIPF relies ultimately on
histopathology (Heikkilä-Laurila and Rajamäki, 2014), ante-mor-
tem lung biopsy is not performed routinely in veterinary practice
due to the invasiveness of the procedure. Moreover, information
obtained from focal biopsy samples may not be representative of
the organ as a whole, especially in view of the spatial heterogeneity
of affected lungs. Again, histopathological ﬁndings in CIPF do not
parallel the typical UIP histological pattern described classically in
human IPF (Syrjä et al., 2013).
In human medicine, the diagnosis of IPF remains challenging
and most cases need to be discussed by a multidisciplinary group. A
conﬁdent diagnosis of IPF can be made in the correct clinical
context when thoracic HRCT images show a pattern of typical or
probable UIP (Lynch et al., 2018). If the clinical context is
indeterminate for IPF, or the computed tomography (CT) pattern
is not indicative of typical or probable UIP, biopsy should be
considered to conﬁrm the presence of the UIP histological pattern,
and a conﬁdent diagnosis of IPF can then be made on the basis of a
multidisciplinary evaluation. The same approach can be advised in
canine medicine for the diagnosis of CIPF.
Blood analyses
Haematological and serum biochemical analyses are generally
unremarkable in WHWTs with CIPF, but are useful in the initial
diagnostic investigation to rule out other possible causes of
exercise intolerance (Heikkilä-Laurila and Rajamäki, 2014).
Cardiopulmonary function tests
Diagnostic tools allowing the investigation of pulmonary
function are limited in dogs in comparison with those available
in human medicine, due to the impracticality of performing
conscious testing. The only two tests that have been investigated
for the overall assessment of the cardiopulmonary function in
WHWTs with CIPF are arterial blood gas analysis and the 6MWT.
Hypoxaemia is a common ﬁnding in WHWTs with CIPF. One
study reported that 45% of dogs had mild hypoxaemia (partialpressure of oxygen in arterial blood (PaO2), 60–80 mmHg) and a
further 45% had severe hypoxaemia (PaO2<60 mmHg) (Heikkilä-
Laurila and Rajamäki, 2014). In comparison with control WHWTs,
WHWTs with CIPF have reduced arterial PaO2 values and increased
alveolar to arterial oxygen gradient (P(A-a)O2), but there is no
difference between groups for the arterial partial pressure of
carbon dioxide (PaCO2) (Heikkilä-Laurila and Rajamäki, 2014).
However, alterations to arterial blood gases are not speciﬁc for CIPF
and other causes of ventilation-perfusion mismatch or right-to-left
shunting (Balakrishnan and King, 2014) should be excluded.
Consequently, arterial blood gas analysis in WHWTs with CIPF is
generally used to quantify the severity of the cardiorespiratory
system dysfunction, rather than to conﬁrm the diagnosis
(Balakrishnan and King, 2014). Interestingly, despite such low
oxygen levels, most of the WHWTs with CIPF are bright, alert, and
not dyspnoeic, suggesting that slow disease progression enables
the dogs to adapt to decreasing blood oxygen levels (Heikkilä-
Laurila and Rajamäki, 2014).
The 6MWT is a submaximal exercise test that measures the
distance an individual is able to walk over 6 min (6MWD) (Lilja-
Maula et al., 2014a). This test is used widely in human clinical
practice to assess disease progression and response to treatment,
as well as in therapeutic trials to serve as a primary end-point, as it
is inexpensive, convenient and well-tolerated (Demir and Küçü-
koglu, 2015). In WHWTs with CIPF, the 6MWT distance was
signiﬁcantly decreased in comparison with controls and had a
moderate positive correlation with PaO2, suggesting that the test
can serve as a non-invasive means of monitoring lung function and
exercise tolerance (Lilja-Maula et al., 2014a).
Echocardiography
Echocardiography is an essential complementary examination
in the diagnostic approach to CIPF. It allows exclusion of any
concomitant primary cardiac disease and, most importantly, it
quantiﬁes pulmonary arterial pressure (PAP) to assess for
secondary pulmonary hypertension (PH), necessary for making
therapeutic decisions. PH is frequent in WHWTs with CIPF
(Schober and Baade, 2006; Roels et al., 2014). In the absence of
cardiac catheterisation, Doppler ﬂow interrogations of tricuspid or
pulmonary insufﬁciency jets are the current echocardiographic
reference standard for the diagnosis of PH in dogs. Other
echocardiographic measures for a non-invasive diagnostic ap-
proach to PH have been developed, including acceleration time to
ejection time ratio of the pulmonary artery ﬂow (AT:ET) (Schober
and Baade, 2006), the main pulmonary artery diameter to aortic
diameter ratio (MPA/Ao) (Serres et al., 2007) and the right
pulmonary artery distensibility index (RPAD Index) (Visser et al.,
2016). Moreover, a new and promising parameter, the right
pulmonary vein to pulmonary artery ratio (PV/PA), was useful in
the detection of pulmonary hypertension of pre-capillary origin in
WHWTs with CIPF (Roels et al., 2014).
Bronchoscopy and bronchoalveolar lavage ﬂuid analysis
Bronchial abnormalities have been reported in a high propor-
tion of WHWTs with CIPF, and include tracheal collapse, bronchial
mucosal irregularity, an increased amount of bronchial mucus,
bronchomalacia, dynamic airway collapse and bronchiectasis
(Corcoran et al., 2011; Heikkilä et al., 2011; Heikkilä-Laurila and
Rajamäki, 2014). These bronchial changes are not speciﬁc for CIPF,
as they occur in other pulmonary diseases (Heikkilä-Laurila and
Rajamäki, 2014), and some may simply be associated with old age,
reﬂecting the population of WHWTs with CIPF (Mercier et al.,
2011). Analysis of the bronchoalveolar lavage ﬂuid (BALF) usually
shows a moderate increase in the total cellular count due to
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(Heikkilä-Laurila and Rajamäki, 2014).
Diagnostic imaging
Thoracic radiographic ﬁndings in WHWTs with CIPF are not
speciﬁc and vary from a generalised broncho-interstitial pattern to
only interstitial, predominantly bronchial or patchy alveolar
opacities, and increased size of the heart silhouette; ﬁndings that
might be observed in other pulmonary diseases (Heikkilä-Laurila
and Rajamäki, 2014). Thoracic radiography can be used to assess for
evidence of other pulmonary diseases, such as neoplasia (Heikkilä-
Laurila and Rajamäki, 2014), which has been described in a few
WHWTs with CIPF.
In humans, HRCT is a standard method for providing diagnostic
and prognostic information, and plays a major role in the IPF
staging process (Raghu, 2011). HRCT has a high predictive value for
the diagnosis of a UIP pattern. In half of human cases, HRCT is
sufﬁcient to allow a conﬁdent diagnosis of IPF. The HRCT pattern
that corresponds to the pathological features of UIP includes the
presence of bilateral, predominantly sub-pleural, basal reticular
abnormalities, the absence of additional features considered
incompatible with a diagnosis of IPF, and the presence of
‘honeycombing’, considered the most speciﬁc feature of the UIP
pattern, with or without traction bronchiectasis (Raghu, 2011).
Several studies report HCRT ﬁndings in WHWTs with CIPF
(Johnson et al., 2005; Corcoran et al., 2011; Heikkilä et al., 2011;
Fitzgerald et al., 2017; Roels et al., 2017a), sometimes in
comparison with ﬁndings in healthy WHWTs (Roels et al.,
2017a; Thierry et al., 2017). All support the use of thoracic CT as
a method for characterising IPF in WHWTs. In the ﬁrst descriptions
of the CT features of CIPF, common ﬁndings mainly included the
presence of a ground-glass pattern and reticular abnormalities,
while traction bronchiectasis and ‘honeycombing’ were only
described in the later stages of the disease (Johnson et al., 2005;
Corcoran et al., 2011; Heikkilä et al., 2011; Fitzgerald et al., 2017). In
a more recent study comparing the effect of sedation and
anaesthesia on thoracic HRCT ﬁndings in WHWTs (both healthy
and with CIPF), and using the glossary of terms of the Fleischner
Society (Roels et al., 2017a), ground-glass opacity (GGO) was
identiﬁed as the most frequent lesion and was present in all image
series from affected WHWTs collected both under sedation and
general anaesthesia. GGO was also the only lesion observed in
control age- and breed-matched dogs, but was less extensive
compared with dogs with CIPF. A mosaic attenuation pattern was
also frequently observed. This study concluded that despite the
differences between GGO and the mosaic attenuation pattern, the
use of sedation to obtain HRCT images may aid diagnosis of CIPF in
WHWTs if general anaesthesia is contraindicated. Another recent
study conﬁrmed that GGO, focal reticular and mosaic attenuation
patterns are the most common CT characteristics of CIPF, with the
GGO pattern considered to represent mild severity, while focal
reticular and mosaic attenuation patterns were associated with
moderate severity (Thierry et al., 2017). Moreover, severity of
pulmonary CT ﬁndings was positively correlated with severity of
clinical signs and negatively associated with survival time after
diagnosis (Thierry et al., 2017). These most recent HRCT studies
(Roels et al., 2017a; Thierry et al., 2017) indicate that CIPF does not
perfectly match IPF, but rather represents a mixed pattern with
characteristics of both UIP and non-speciﬁc interstitial pneumonia
(NSIP).
Histopathological features
In humans, IPF presents a histopathological image of UIP, which
is characterised by areas of marked interstitial pulmonary ﬁbrosis,‘honeycombing’ and distortion of the alveolar architecture in a
patchy, often sub-pleural or para-septal pattern and by character-
istic ﬁbroblastic foci at the periphery of the lesions (Katzenstein
et al., 2008; Raghu, 2011). The ﬁrst reports related to histopathol-
ogy of CIPF in WHWTs, based on limited sample numbers, reported
differences in the histopathological appearance of the pulmonary
lesions in WHWTs and those characterising UIP in humans
(Corcoran et al., 1999a; Norris et al., 2005; Eriksson et al., 2009;
Heikkilä et al., 2011). In a later study describing the pulmonary
histopathological ﬁndings in 18 WHWTs with CIPF (Syrjä et al.,
2013), an underlying diffuse mature ﬁbrosis resembling human
NSIP more than UIP was seen in the lungs of all affected dogs.
Additionally, the majority of dogs with CIPF showed multifocal
areas of accentuated sub-pleural and peri-bronchiolar ﬁbrosis with
occasional ‘honeycombing’ and profound alveolar epithelial
changes, reminiscent of human UIP and not commonly seen in
NSIP. Interstitial ﬁbroblastic foci, characteristic of UIP, were not
seen. Therefore, CIPF in WHWTs, although presenting with
histological changes typical of UIP, also shares features of both
human UIP and NSIP, providing further evidence that CIPF and
human IPF are not identical.
Biomarkers
Several studies have been conducted to identify biomarkers
able to differentiate CIPF from other chronic lower respiratory
diseases (i.e. diagnostic biomarkers), to act as a surrogate for
disease severity, and/or to predict outcome (i.e. prognostic
biomarkers). Although several interesting candidate biomarkers
have been proﬁled in human IPF, large-scale multicentric
studies are needed to conﬁrm the utility of single or multiple
biomarkers.
In CIPF, both screening and targeted approaches have been
used to identify relevant biomarkers. Screening technologies
consist of an unbiased approach, which favours exploratory
identiﬁcation of new biomarkers, and which can potentially
lead to the identiﬁcation of new disease pathways and
therefore to possibilities of discovering novel anti-ﬁbrotic
agents. In this context, pulmonary gene expression by micro-
array analysis (Krafft et al., 2013) and analysis of the BALF
proteome (Lilja-Maula et al., 2013) have been performed.
Pulmonary gene expression was analysed using a speciﬁc
canine microarray coupled with Ingenuity Pathway Analysis, a
bioinformatics tool, in lung samples from dogs with CIPF and
healthy control dogs (Krafft et al., 2013). Up-regulation of
numerous genes was demonstrated, with increased expression
of the chemokine-encoding genes chemokine ligand 2 (CCL2),
chemokine ligand 7 (CCL7), chemokine (C-X-C motif) ligand 14
(CXCL14) and interleukin 8 (IL-8; also known as chemokine [C-
X-C motif] ligand 8 [CXCL8]), and ﬁbroblast activation protein α
gene (FAP), conﬁrmed by quantitative reverse transcriptase
PCR (qRT-PCR). All of these genes encode proteins with
potential biomarker utility. Differential gel electrophoresis
and liquid chromatography-tandem mass spectrometry were
used for proteomic analysis and protein identiﬁcation in BALF
obtained from dogs with CIPF or chronic bronchitis and healthy
dogs; the study failed to identify speciﬁc biomarkers for CIPF
(Lilja-Maula et al., 2013).
A targeted approach was used to select other biomarkers, based
on their previously demonstrated direct or indirect pro-ﬁbrotic
effects, or based on their proven relevance as diagnostic and/or
prognostic biomarkers in human IPF. Those biomarkers included
procollagen type III amino terminal pro-peptide (PIIINP) (Heikkilä
et al., 2013), endothelin-1 (ET-1) (Krafft et al., 2011), transforming
growth factor beta-1 (TGF-β1) (Krafft et al., 2014), CCL2 (Roels
et al., 2015a,b), IL-8 (Roels et al., 2015a,b), 5-hydroxytryptamine-
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factor (VEGF) (Roels et al., 2015a), Krebs Von den Lungen-6 (KL6)
(Fastrès et al., 2018) and C-reactive-protein (CRP) (Viitanen et al.,
2014). Among those biomarkers, CCL2, IL-8, ET-1 and PIIINP were
elevated in the BALF of WHWTs with CIPF compared with healthy
WHWTs, while only CCL2 and ET-1 were elevated in the serum of
affected WHWTs compared with healthy WHWTs (Krafft et al.,
2011; Heikkilä et al., 2013; Roels et al., 2015a,b). Furthermore, the
blood concentrations of IL-8 (Roels et al., 2015a), TGF-β1 (Krafft
et al., 2014) and KL6 (Fastrès et al., 2018) were signiﬁcantly higher
in the serum of healthy WHWTs in comparison with healthy age-
matched dogs from breeds non-predisposed to CIPF. The presence
of such high circulating concentrations of these mediators in the
predisposed breed is possibly related to, or indicative of the
predisposition of the WHWT breed to CIPF.
Long-term outcome, prognostic indicators
CIPF in WHWTs can have a rapid or slow disease progression
(Lilja-Maula et al., 2014a) and some dogs can experience acute
worsening of their respiratory function during the course of the
disease (Heikkilä et al., 2013). In a study that investigated the long-
term survival in WHWTs with CIPF, the median IPF-speciﬁc
survival of dogs that had died was 32 months from the onset of
clinical signs. According to an online questionnaire–based survey
answered by 458 WHWT owners (Roels et al., 2018), the overall
survival time after diagnosis was 1.4 years (0–8.5 years), and cause
of death was CIPF-related in 76.7% of cases.
Very few prognostic factors have been identiﬁed. Measured
PaO2 and 6MWT distance were studied, but did not correlate with
survival (Lilja-Maula et al., 2014a). High CCL2 blood concentration
at the time of diagnosis (Roels et al., 2015a,b) and the severity of
pulmonary CT ﬁndings were shown to be negatively associated
with survival time after diagnosis (Thierry et al., 2017).
Treatment
At present, no effective treatments for CIPF have been
described and no therapeutic trials have been performed. The
current therapy aims to reduce clinical signs on an individual
basis, and to alleviate possible complications that can develop
during the course of the disease. Oral or inhaled corticosteroids
appear to relieve cough in many dogs, particularly in the
presence of concurrent bronchial changes (Corcoran et al.,
1999a; Heikkilä et al., 2013). When concomitant pulmonary
hypertension is present, improvement in clinical signs and a
decrease in PAP after treatment with sildenaﬁl has been
reported (Kellihan et al., 2015).
In human IPF, recent anti-ﬁbrotic therapies including pirfeni-
done and nintedanib have proven efﬁcacy in slowing the course of
disease (Hughes et al., 2016); however, their effect has not been
documented in CIPF. Response to speciﬁc anti-ﬁbrotic treatment
has not yet been investigated in WHWTs with CIPF.
Conclusions
CIPF affects middle-aged to older WHWTs and the disease
mimics human IPF, although CT and histopathological ﬁndings are
not identical. Despite these dissimilarities, CIPF might be an
interesting, spontaneously arising disease model for the study of
human IPF. Due to the unique breed predisposition, a genetic
component is suspected, but has not yet been identiﬁed. Despite
numerous investigations over the past decade, the aetiopatho-
genesis of CIPF is not yet elucidated and no speciﬁc treatment
exists, emphasising the need to identify novel therapeutic
strategies in the future.Conﬂict of interest statement
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